PSTV - Plus Therapeutics Inc
IEX Last Trade
1.42
0 0%
Share volume: 7,603
Last Updated: Fri 30 Aug 2024 07:10:40 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.42
0.00
0.00%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-07-21 | 2022-10-20 | 2023-02-23 | 2023-04-20 | 2023-08-14 | 2023-10-31 | 2024-03-05 | 2024-05-15 | |
| Total revenue | 0.000 | 73.000 K | 151.000 K | 506.000 K | 1.854 M | 1.240 M | 1.313 M | 1.677 M | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 73.000 K | 151.000 K | 506.000 K | 1.854 M | 1.240 M | 1.313 M | 1.677 M | |
| inf% | 106.85% | 235.10% | 266.40% | -33.12% | 5.89% | 27.72% | |||
| Operating expenses | 5.120 M | 5.167 M | 5.723 M | 5.226 M | 3.344 M | 4.491 M | 5.173 M | 4.976 M | |
| Selling general and admin | 2.289 M | 2.222 M | 3.586 M | 2.243 M | 1.924 M | 1.998 M | 2.379 M | 2.213 M | |
| Research and development | 2.831 M | 2.945 M | 2.137 M | 2.983 M | 1.420 M | 2.493 M | 2.794 M | 2.763 M | |
| Total expenses | 5.120 M | 5.167 M | 5.723 M | 5.226 M | 3.344 M | 4.491 M | 5.173 M | 4.976 M | |
| 0.92% | 10.76% | -8.68% | -36.01% | 34.30% | 15.19% | -3.81% | |||
| Operating income | -5.120 M | -5.094 M | -5.572 M | -4.720 M | -1.490 M | -3.251 M | -3.860 M | -3.299 M | |
| Ebit | -5.120 M | -5.094 M | -5.572 M | -4.720 M | -1.490 M | -3.251 M | -3.860 M | -3.299 M | |
| Pretax income | -5.282 M | -5.219 M | -5.658 M | -4.805 M | -1.482 M | -3.219 M | -3.810 M | -3.261 M | |
| -1.19% | 8.41% | -15.08% | -69.16% | 117.21% | 18.36% | -14.41% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | -5.282 M | -5.219 M | -5.658 M | -4.805 M | -1.482 M | -3.219 M | -3.810 M | -3.261 M | |
| 1.19% | -8.41% | 15.08% | 69.16% | -117.21% | -18.36% | 14.41% | |||
| Net income | -5.282 M | -5.219 M | -5.658 M | -4.805 M | -1.482 M | -3.219 M | -3.810 M | -3.261 M | |
| 1.19% | -8.41% | 15.08% | 69.16% | -117.21% | -18.36% | 14.41% |